RSV vaccines Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Arexvy® RSV vaccine safety data – older adults Shingrix® AusVaxSafety is conducting active vaccine safety surveillance of recently introduced respiratory syncytial virus (RSV) vaccines in Australia to ensure their ongoing safety.The RSV vaccines registered for use in Australia are:Arexvy® – registered for use in adults aged 60 years and overAbrysvo® – registered for use in pregnant people and adults aged 60 years and over.Safety data are gathered via the AusVaxSafety surveillance program and are based on vaccine safety surveys sent in the days following RSV vaccination. Data on this page are updated monthly.Latest RSV vaccine safety dataClick on the tiles below to view AusVaxSafety RSV vaccine safety data for specific age and population groups.Note: Vaccine safety data for additional population groups and other RSV vaccines will be added once enough data are collected to enable meaningful analysis. Arexvy® RSV vaccine safety data – older adults View the latest Arexvy® RSV vaccine safety data here Vaccine safety data Main navigation COVID-19 vaccines Influenza vaccines Mpox (monkeypox) vaccine National Immunisation Program schedule vaccines Nirsevimab RSV vaccines Arexvy® RSV vaccine safety data – older adults Shingrix® News & events All news & events 08 November 2024 | News Enhanced National Immunisation Program vaccine safety data now available 23 October 2024 | News AusVaxSafety study affirms short-term safety profile of Moderna and Novavax COVID-19 vaccine priming doses 01 October 2024 | News AusVaxSafety marks a decade of progress in vaccine safety 12 September 2024 | News AusVaxSafety surveillance of 2024 seasonal flu vaccines concludes with no safety issues identified